Cabergoline is a selective D2DR (D2-like receptor) agonist, similarly displaying a high affinity for several serotonin receptor subtypes. Cabergoline exhibits an inhibitory effect of the secretion of prolactin and growth hormone and has been shown to reverse levodopa-induced dyskinesias in Parkinsonian monkeys. Cabergoline is an activator of D3DR.
Eguchi et al (1995) Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors:in vitro culture studies. Endocr.J. 42 413. Hadj Tahar et al (2000) Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Cin.Neuropharmacol. 23 195. Kvernmo et al (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin.Ther. 28 1065.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.